Verdiva Bio
Agent21Agent Readiness: 21/100. Bottom 25%. Measured by StartupHub.ai. Median 41.Trust81Data Trust: 81/100. Top 25%. Measured by StartupHub.ai. Median 61.Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.
About
Verdiva Bio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for obesity and cardiometabolic diseases. Their pipeline includes both oral and injectable therapies designed to enhance efficacy, improve patient convenience, and achieve better long-term outcomes, with a particular emphasis on patient-friendly options like once-weekly dosing. The company leverages advancements in gut-brain biology to create novel medicines addressing significant unmet medical needs globally.
Listed competitors
Global healthcare company focused on diabetes care, obesity, and rare blood disorders.
Global pharmaceutical company focused on developing and manufacturing medicines.
A global biotechnology company discovering, developing, manufacturing, and delivering innovative human therapeutics.
Also in this space
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
Shares Biotechnology, Pharmaceuticals
Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.
Shares Biotechnology, Drug Discovery
Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
Shares Biotechnology, Pharmaceuticals
Key facts
- Website
- verdivabio.com
- Headquarters
- San Diego, United States
- Founded
- 2021
- Employees
- 74
- Total funding
- $170M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 28 Jun 2023 | Series B | $120M | Arch Venture Partners |
| 11 Jan 2022 | Seed | $50M | Arch Venture Partners |
Tech stack
Detected on verdivabio.com, last scanned 21 Oct 2026. Run your own scan
- Compliance
- GDPR, CCPA
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- Email provider
- Microsoft 365
Verdiva Bio scores 17. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Verdiva Bio trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Verdiva Bio is 81 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Verdiva Bio raised?
Verdiva Bio has raised a total of $170M in funding. The most recent round on record is Series B.
How many employees does Verdiva Bio have?
Verdiva Bio has approximately 74 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Verdiva Bio
